拆解礼来最新减重新药ELORATZP的惊人试验数据,揭秘减肥药从单靶点进化到多激素联合的技术路径,客观分析其疗效与潜在副作用,带你读懂减重领域的前沿进展。
参考文献:
Eli Lilly and Company. Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes. 2026-09-30. 新闻稿
Billings LK, et al. EloraTZP Phase 2b trial (NCT06603571), presented at EASD 2026 Annual Meeting, Milan.
Campbell P. EASD 2026: EloraTZP Bests Tirzepatide on Weight Loss, A1C in Type 2 Diabetes. ConsultantLive, 2026-09-30.
Eli Lilly. Retatrutide (GLP-1/GIP/glucagon triple agonist) Phase 3 results, EASD 2026; published in The Lancet, 2026-09.
Novo Nordisk. CagriSema (cagrilintide + semaglutide) REIMAGINE Phase 3 trials; FDA decision expected by end of 2026.
Lee J. Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. MarketWatch, 2026-09-30.

